[go: up one dir, main page]

CN107488153B - Afatinib intermediate compound - Google Patents

Afatinib intermediate compound Download PDF

Info

Publication number
CN107488153B
CN107488153B CN201610411343.6A CN201610411343A CN107488153B CN 107488153 B CN107488153 B CN 107488153B CN 201610411343 A CN201610411343 A CN 201610411343A CN 107488153 B CN107488153 B CN 107488153B
Authority
CN
China
Prior art keywords
reaction
organic solvent
compound
afatinib
catalyst
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201610411343.6A
Other languages
Chinese (zh)
Other versions
CN107488153A (en
Inventor
张贵民
赵绪亮
王秀娟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong New Time Pharmaceutical Co Ltd
Original Assignee
Shandong New Time Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong New Time Pharmaceutical Co Ltd filed Critical Shandong New Time Pharmaceutical Co Ltd
Priority to CN201610411343.6A priority Critical patent/CN107488153B/en
Publication of CN107488153A publication Critical patent/CN107488153A/en
Application granted granted Critical
Publication of CN107488153B publication Critical patent/CN107488153B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a novel intermediate II of afatinib and a preparation method thereof, and the preparation method comprises the following steps: reducing N- (3-chloro-4-fluorophenyl) -7-fluoro-6-nitro-4-quinazolinamine to obtain N- (3-chloro-4-fluorophenyl) -7-fluoro-6-amino-4-quinazolinamine IV, carrying out condensation reaction with diethylphosphonoacetic acid to obtain III, and carrying out Wittig-Horner-Emmons reaction with dimethylamino acetaldehyde diethyl acetal to obtain a key intermediate II. The method has high yield and high purity.

Description

Afatinib intermediate compound
Technical Field
The invention belongs to the field of pharmaceutical chemistry, and particularly relates to an afatinib intermediate compound.
Background
Afatinib maleate is a multi-target oral small molecule drug developed by bliringer-jehn, germany, and is an irreversible inhibitor of Epidermal Growth Factor Receptor (EGFR) and human epidermal receptor 2(HER2) tyrosine kinase. It is a second generation highly potent dual non-reversible tyrosine kinase inhibitor. The drug was approved by the U.S. FDA in 2013 on 7, 12 months. Under the trade name Gilotrif.
Afatinib maleate (I) with the chemical name 4- [ (3-chloro-4-fluorophenyl) amino ] -6- { [4- (N, N-dimethylamino) -1-oxo-2-buten-1-yl ] amino } -7- ((S) -tetrahydrofuran-3-yloxy) -quinazoline dimaleate.
Figure BDA0001013706980000011
The preparation method of afatinib is reported in the primary chinese patent CN1867564B of the business of bouling invager: taking mother nucleus 4- [ (3-chloro-4-fluorophenyl) amino ] -6-nitro-7-fluoroquinazoline (V) as an initial raw material, and carrying out substitution reaction of halogen fluorine with S-3-hydroxy-tetrahydrofuran under the catalysis of a basic catalyst potassium tert-butoxide to generate 4- [ (3-chloro-4-fluorophenyl) amino ] -6-nitro-7- [ (S) - (tetrahydrofuran-3-yl) oxy ] quinazoline (1); the intermediate (1) is reduced by a nitro group at the 6-position to obtain a corresponding amino compound (2); the compound (2) and diethyl phosphoacetic acid are subjected to amidation reaction to obtain an intermediate (3), and the intermediate (3) and dimethylamino acetaldehyde diethyl acetal are subjected to Wittig-Horner-Emmons reaction to obtain afatinib (I).
Figure BDA0001013706980000021
According to other literature analysis, the starting material V is in butt joint with the chiral intermediate S-3-hydroxy-tetrahydrofuran, and then subsequent reaction is carried out to obtain the afatinib. The following defects are found in the prior literature through experiments:
the chiral intermediate S-3-hydroxy-tetrahydrofuran is expensive and has large loss in subsequent multi-step reactions;
the final product I produced by the Wittig-Horner-Emmons reaction carried out by the intermediate 3 has more impurities and is not easy to remove.
In order to solve the problems, it is necessary to find a more economical and practical route for synthesizing afatinib.
Disclosure of Invention
The invention aims to search for a new preparation way, and provides a preparation method of afatinib according to an atom economic synthesis concept of green chemistry.
The main technical scheme provided by the invention is as follows: an afatinib intermediate compound II has a structural formula as follows:
Figure BDA0001013706980000031
a preparation method of an intermediate II comprises the following steps: n- (3-chloro-4-fluorophenyl) -7-fluoro-6-nitro-4-quinazolinamine V is used as an initial raw material to be reduced to obtain N- (3-chloro-4-fluorophenyl) -7-fluoro-6-amino-4-quinazolinamine IV, the N- (3-chloro-4-fluorophenyl) -7-fluoro-6-amino-4-quinazolinamine IV is subjected to condensation reaction with diethylphosphonoacetic acid to obtain III, and the III is subjected to Wittig-Horner-Emmons reaction with dimethylaminoacetaldehyde diethyl acetal to obtain a key intermediate II.
Figure BDA0001013706980000032
Specifically, the method comprises the following steps:
1) reduction reaction: and adding the starting material V, a reducing agent, a catalyst and an organic solvent A into a reaction bottle for reduction reaction to obtain a compound IV.
2) Condensation reaction: and adding the compound IV, the diethylphosphonoacetic acid, the condensing agent and the organic solvent B into a reaction bottle for condensation reaction to obtain a compound III.
3) Wittig-Horner-Emmons reaction: adding the compound III, dimethylamino acetaldehyde diethyl acetal, concentrated hydrochloric acid, an organic solvent C and alkali A into a reaction bottle for reaction to obtain a compound II.
The organic solvent A, the organic solvent B and the organic solvent C are respectively and independently selected from one or more of aromatic hydrocarbons, aliphatic hydrocarbons, alicyclic hydrocarbons, halogenated hydrocarbons, alcohols, ethers, amides, glycol derivatives, ester solvents and phenol; more preferably one or more of benzene, toluene, cyclohexane, methanol, ethanol, t-butanol, diethyl ether, acetone, trichloroethylene, tetrahydrofuran, methyl t-butyl ether, ethyl acetate and DMF.
In the reduction reaction, the organic solvent A is preferably one or more of tert-butyl alcohol, diethyl ether, acetone, trichloroethylene, tetrahydrofuran, methyl tert-butyl ether, ethyl acetate and DMF; most preferably t-butanol or acetone or a mixture of both.
In the reduction reaction, the catalyst is selected from one of 10% Pd/C, Zn, Fe (OH)3, FeO (OH), FeCl3 and Fe (OAc)2, and FeCl is preferred3Or 10% Pd/C. Preferably, the amount of catalyst added is 0.03 to 0.05 times the amount of intermediate V.
In the reduction reaction, the reducing agent is selected from one of H2/Ni, LiAlH4, NaBH4, hydrogen, ammonium formate, hydrazine hydrate and ammonium chloride, and is further preferably selected from one of hydrogen, ammonium formate, hydrazine hydrate and ammonium chloride; more preferably hydrogen.
In the condensation reaction, the condensing agent is selected from one of 1, 3-Dicyclohexylcarbodiimide (DCC), N '-Carbonyldiimidazole (CDI) and 1,1' -carbonylbis (1,2, 4-triazole) (CDT). Preferably, the amount of the condensing agent added is 0.3 to 1.5 times the amount of the intermediate IV.
In the condensation reaction, the organic solvent B is preferably one or more of tert-butyl alcohol, diethyl ether, acetone, trichloroethylene, tetrahydrofuran, methyl tert-butyl ether, ethyl acetate and DMF; most preferred is tetrahydrofuran or methyl tert-butyl ether.
The base A in the wittig-Horner reaction is selected from organic bases or inorganic bases, preferably inorganic bases, and the inorganic bases are preferably 25% inorganic base aqueous solution. The inorganic base is selected from one of potassium hydroxide, sodium hydroxide, lithium hydroxide and cesium hydroxide, most preferably potassium hydroxide.
In the wittig-Horner reaction, the organic solvent C is preferably one or more of methanol, tert-butyl alcohol, diethyl ether, acetone, trichloroethylene, tetrahydrofuran, methyl tert-butyl ether, ethyl acetate and DMF; tetrahydrofuran is most preferred.
Preferably, the reduction reaction step is to take the compound V, a catalyst and absolute ethyl alcohol and put the compound V and the catalyst into a single-mouth bottle, start electromagnetic stirring, replace air with nitrogen, replace nitrogen with hydrogen, keep the temperature and maintain the pressure for reaction, after the reaction is finished, remove the catalyst by decompression and suction filtration, and evaporate filtrate in a rotary manner to dryness to obtain an intermediate IV.
Preferably, the reduction reaction step comprises the steps of taking the compound V, a catalyst and absolute ethyl alcohol, placing the mixture into a single-mouth bottle, starting electromagnetic stirring, replacing air with nitrogen for 3 times, replacing nitrogen with hydrogen for 3 times, carrying out heat preservation and pressure maintaining reaction for 4 hours, after the reaction is finished, carrying out reduced pressure suction filtration to remove the catalyst, and carrying out rotary evaporation on filtrate until the filtrate is dried to obtain an intermediate IV.
Preferably, the condensation reaction step is: and putting the diethylphosphonoacetic acid and tetrahydrofuran into a three-neck flask, starting stirring, slowly adding a condensing agent, carrying out heat preservation reaction, then adding the intermediate IV, continuing the heat preservation reaction, separating out a large amount of solid after the reaction is finished, adding methyl tert-butyl ether, stirring, carrying out suction filtration, and drying to obtain an intermediate III.
Further preferably, the condensation reaction step is: putting the diethylphosphonoacetic acid and the tetrahydrofuran into a three-neck flask, starting stirring, slowly adding the condensing agent, keeping the temperature at 40 ℃ for reaction for 1h, then adding the intermediate IV, keeping the temperature for reaction for 1h, separating out a large amount of solids after the reaction is finished, adding the methyl tert-butyl ether, stirring for 1h, carrying out suction filtration, and drying to obtain an intermediate III.
Preferably, the Wittig-Horner-Emmons reaction step is first to deprotect the dimethylaminoethanol to yield dimethylaminoacetaldehyde. Weighing the intermediate III, placing the intermediate III in a three-neck flask, adding tetrahydrofuran solution of tetrahydrofuran and dimethylaminoacetaldehyde, stirring for dissolving, cooling to 0 ℃ in an ice bath, starting dropwise adding inorganic alkaline aqueous solution, controlling the temperature to be 0-5 ℃, naturally heating to room temperature after dropwise adding, pouring reaction liquid into water after reaction, stirring for crystallization, performing suction filtration, and drying to obtain an intermediate II.
A method for preparing afatinib by using the intermediate II, the intermediate II and (S) -3-hydroxytetrahydrofuran are subjected to substitution reaction to obtain a compound I,
Figure BDA0001013706980000051
the substitution reaction comprises the following specific steps: and adding the compound II, (S) -3-hydroxytetrahydrofuran, alkali B and an organic solvent D into a reaction bottle for substitution reaction to obtain a compound I.
In the substitution reaction, the organic solvent D is selected from one of aromatic hydrocarbon, aliphatic hydrocarbon, alicyclic hydrocarbon, halogenated hydrocarbon, alcohol, ether, amide, glycol derivative, ester solvent and phenol; more preferably one selected from benzene, toluene, cyclohexane, methanol, ethanol, t-butanol, diethyl ether, acetone, trichloroethylene, tetrahydrofuran, methyl t-butyl ether, ethyl acetate and DMF; most preferably tert-butanol.
In the substitution reaction, the base B is selected from one of sodium hydride, potassium hydride, calcium hydride and potassium tert-butoxide, and potassium tert-butoxide is more preferred.
Preferably, the substitution reaction is carried out, the intermediate II is weighed and placed in a three-necked bottle, tert-butyl alcohol is added, then (S) -3-hydroxytetrahydrofuran is added, potassium tert-butoxide is slowly added, the temperature is controlled to be not more than 50 ℃, the addition is completed, the stirring reaction is carried out for 1h, after the reaction is completed, the reaction liquid is poured into drinking water, 10% acetic acid water solution is used for regulating the pH value to be 6-7, and afatinib I is obtained through suction filtration and drying.
The final product of the route has less impurities and low cost, and is suitable for industrial production. The chiral intermediate S-3-hydroxy-tetrahydrofuran is used in the last step of the substitution reaction, so that the loss of expensive intermediates in multi-step reactions is reduced.
Detailed Description
In order to make the technical solutions of the present invention better understood by those skilled in the art, the following non-limiting examples are disclosed to further illustrate the present invention.
Example 1
The first step is as follows:
3.4g of compound V and 153mgFeCl were taken350mL of mixed solution of ethanol and acetone (the volume ratio of ethanol to acetone is 3:4) is put into a single-mouth bottle, electromagnetic stirring is started, air is replaced by nitrogen for 3 times, nitrogen is replaced by hydrogen for 3 times, heat preservation and pressure maintaining are carried out for 4 hours, after the reaction is finished, the catalyst is removed by vacuum filtration, filtrate is evaporated to dryness in a rotary manner, and the yield is 99.6%.
The second step is that:
2.0g of diethylphosphonoacetic acid and 50ml of tetrahydrofuran are put into a 250ml three-necked flask, stirring is started, 2.0g of CDI is slowly added, the temperature is kept at 40 ℃ for 1 hour of reaction, then 3.0g of intermediate IV is added, the temperature is kept for 1 hour of reaction, after the reaction is finished, a large amount of solid is separated out, 50ml of methyl tert-butyl ether is added, stirring is carried out for 1 hour, and then suction filtration and drying are carried out to obtain an intermediate III, wherein the yield is 98.1%.
The third step:
firstly, dimethyl amino acetaldehyde diethyl acetal is deprotected to generate dimethyl amino acetaldehyde.
Weighing 4.5g of the intermediate III, placing the intermediate III into a 250ml three-neck flask, adding 50ml of tetrahydrofuran and 40ml of a tetrahydrofuran solution of dimethylaminoacetaldehyde, stirring and dissolving, cooling to 0 ℃ in an ice bath, starting to dropwise add 30g of 25% KOH aqueous solution, controlling the temperature to be 0-5 ℃, after dropwise adding, naturally heating to room temperature, pouring reaction liquid into 300ml of water after the reaction is finished, stirring and crystallizing for 2 hours, performing suction filtration, and drying to obtain an intermediate II, wherein the yield is 97.4%, and the purity is 99.8%.
The fourth step
Weighing 4.0g of the intermediate II, placing the intermediate II in a 250ml three-necked bottle, adding 50ml of tert-butyl alcohol, adding 1.0g of (S) -3-hydroxytetrahydrofuran, slowly adding potassium tert-butoxide, controlling the temperature to be not more than 50 ℃, stirring for reaction for 1h, pouring the reaction liquid into 200ml of drinking water after the reaction is finished, adjusting the pH value to 6.5 by using 10% acetic acid aqueous solution, performing suction filtration, and drying to obtain the afatinib I, wherein the yield is 89%, the purity is 99.6%, and the single impurity content is less than 0.1%.
Example 2
The first step is as follows:
3.4g of the compound V, 102mg of 10% Pd/C and 50mL of methyl tert-butyl ether are put into a single-mouth bottle, electromagnetic stirring is started, air is replaced by nitrogen for 3 times, nitrogen is replaced by hydrogen for 3 times, heat preservation and pressure maintaining are carried out for 4 hours, after the reaction is finished, the catalyst is removed by vacuum filtration, filtrate is evaporated to dryness in a rotary manner, and the yield is 99.1%.
The second step is that:
2.0g of diethylphosphonoacetic acid and 50ml of methyl tert-butyl ether are put into a 250ml three-necked flask, stirring is started, 4.5g of CDI is slowly added, the temperature is kept at 40 ℃ for 1h of reaction, then 3.0g of intermediate IV is added, the temperature is kept for 1h of reaction, after the reaction is finished, a large amount of solid is separated out, 50ml of methyl tert-butyl ether is added, stirring is carried out for 1h, suction filtration is carried out, and drying is carried out to obtain an intermediate III, wherein the yield is 97.1%.
The third step:
firstly, dimethyl amino acetaldehyde diethyl acetal is deprotected to generate dimethyl amino acetaldehyde.
Weighing 4.5g of the intermediate III, placing the intermediate III in a 250ml three-necked bottle, adding 50ml of DMF and 40ml of DMF solution of dimethylaminoacetaldehyde, stirring and dissolving, cooling to 0 ℃ in an ice bath, beginning to dropwise add 30g of 25% NaOH aqueous solution, controlling the temperature to be 0-5 ℃, after dropwise addition, naturally heating to room temperature, pouring reaction liquid into 300ml of water after reaction, stirring and crystallizing for 2 hours, performing suction filtration, and drying to obtain an intermediate II, wherein the yield is 96.2% and the purity is 99.6%.
The fourth step
Weighing 4.0g of the intermediate II, placing the intermediate II in a 250ml three-necked bottle, adding 50ml of acetone, adding 1.0g of (S) -3-hydroxytetrahydrofuran, slowly adding sodium hydride, controlling the temperature to be not more than 50 ℃, stirring for reacting for 1h, pouring the reaction liquid into 200ml of drinking water after the reaction is finished, adjusting the pH value to 7 by using 10% acetic acid aqueous solution, performing suction filtration, and drying to obtain afatinib I, wherein the yield is 87%, the purity is 99.6%, and the single impurity content is less than 0.1%.
Example 3
The first step is as follows:
collecting 3.4g of Compound V, 170mgFe (OH)3Putting 100mL of acetone into a single-mouth bottle, starting electromagnetic stirring, replacing air with nitrogen for 3 times, replacing nitrogen with hydrogen for 3 times, keeping the temperature and maintaining the pressure for reaction for 6 hours, reducing the pressure and filtering to remove the catalyst after the reaction is finished, and rotatably steaming the filtrate until the filtrate is dryIntermediate IV is obtained by drying, and the yield is 99.0%.
The second step is that:
2.0g of diethylphosphonoacetic acid and 80ml of methanol are put into a 250ml three-necked flask, stirring is started, 0.9g of DCC is slowly added, the temperature is kept at 40 ℃ for 1h of reaction, then 3.0g of intermediate IV is added, the temperature is kept for 1h of reaction, after the reaction is finished, a large amount of solid is separated out, 50ml of methanol is added, stirring is carried out for 1h, suction filtration is carried out, and drying is carried out to obtain an intermediate III, wherein the yield is 96.2%.
The third step:
firstly, dimethyl amino acetaldehyde diethyl acetal is deprotected to generate dimethyl amino acetaldehyde.
Weighing 4.5g of the intermediate III, placing the intermediate III in a 250ml three-necked bottle, adding 50ml of ethanol and 40ml of ethanol solution of dimethylaminoacetaldehyde, stirring and dissolving, cooling to 0 ℃ in an ice bath, beginning to dropwise add 30g of 25% LiOH aqueous solution, controlling the temperature to be 0-5 ℃, after dropwise addition, naturally heating to room temperature, after the reaction is finished, pouring the reaction liquid into 300ml of water, stirring and crystallizing for 2 hours, performing suction filtration, and drying to obtain an intermediate II, wherein the yield is 95.1% and the purity is 99.5%.
The fourth step
Weighing 4.0g of the intermediate II, placing the intermediate II in a 250ml three-necked bottle, adding 50ml of ethyl acetate, adding 1.0g of (S) -3-hydroxytetrahydrofuran, slowly adding potassium hydride, controlling the temperature to be not more than 50 ℃, stirring for reacting for 1h, pouring the reaction liquid into 200ml of drinking water after the reaction is finished, adjusting the pH value to be 6 by using 10% acetic acid aqueous solution, performing suction filtration, and drying to obtain afatinib I, wherein the yield is 87%, the purity is 99.5%, and the single impurity content is less than 0.1%.
Comparative example 1
The first step is as follows:
taking 3.4g of a compound V, 80mg of a catalyst, 10% palladium-carbon and 100mL of methanol, putting the mixture into a single-opening bottle, starting electromagnetic stirring, replacing air with nitrogen for 3 times, replacing nitrogen with hydrogen for 3 times, carrying out heat preservation and pressure maintaining reaction for 2 hours, after the reaction is finished, carrying out reduced pressure suction filtration to remove the catalyst, and carrying out rotary evaporation on filtrate until the filtrate is dried to obtain an intermediate IV, wherein the yield is 95.2%.
The second step is that:
2.0g of diethylphosphonoacetic acid and 80ml of methanol are put into a 250ml three-necked bottle, stirring is started, 5.2g of condensing agent DCC is slowly added, the temperature is kept at 48 ℃ for 2 hours of reaction, then 3.0g of intermediate IV is added, the temperature is kept for 2 hours of reaction, after the reaction is finished, a large amount of solid is separated out, 50ml of methanol is added, stirring is carried out for 2 hours, and then suction filtration and drying are carried out to obtain intermediate III, wherein the yield is 88.6%.
The third step:
firstly, dimethyl amino acetaldehyde diethyl acetal is deprotected to generate dimethyl amino acetaldehyde.
Weighing 4.5g of the intermediate III, placing the intermediate III in a 250ml three-necked bottle, adding 50ml of ethanol and 40ml of ethanol solution of dimethylaminoacetaldehyde, stirring and dissolving, cooling to 0 ℃ in an ice bath, beginning to dropwise add 25g of 20% LiOH aqueous solution, controlling the temperature to be 10-15 ℃, after dropwise addition, naturally heating to room temperature, after the reaction is finished, pouring the reaction liquid into 300ml of water, stirring and crystallizing for 2 hours, performing suction filtration, and drying to obtain an intermediate II, wherein the yield is 81.3%, and the purity is 98.2%.
The fourth step
Weighing 4.0g of the intermediate II, placing the intermediate II in a 250ml three-necked bottle, adding 50ml of heptane, adding 1.0g of (S) -3-hydroxytetrahydrofuran, slowly adding lithium hydroxide, controlling the temperature to be not more than 50 ℃, stirring for reacting for 1h, pouring the reaction liquid into 200ml of drinking water after the reaction is finished, adjusting the pH value to be 6.5 by using 10% acetic acid aqueous solution, performing suction filtration, and drying to obtain afatinib I, wherein the yield is 78% and the purity is 95.2%.
Comparative example 2
The first step is as follows:
taking 3.4g of compound V and 200mg of catalyst PdCl2Putting DTBPF and 100mL of methanol into a single-mouth bottle, starting electromagnetic stirring, replacing air with nitrogen for 3 times, replacing nitrogen with hydrogen for 3 times, preserving heat and maintaining pressure for reaction for 3 hours, reducing pressure and filtering to remove the catalyst after the reaction is finished, and rotatably steaming the filtrate to be dry to obtain an intermediate IV with the yield of 89.2%.
The second step is that:
2.0g of diethylphosphonoacetic acid and 80ml of methanol are put into a 250ml three-necked bottle, stirring is started, 2.0g of condensing agent DMC is slowly added, the temperature is kept at 40 ℃ for 2 hours of reaction, then 3.0g of intermediate IV is added, the temperature is kept for 2 hours of reaction, after the reaction is finished, a large amount of solid is separated out, 50ml of methanol is added, stirring is carried out for 2 hours, suction filtration is carried out, and drying is carried out to obtain an intermediate III, wherein the yield is 78.9%.
The third step:
firstly, dimethyl amino acetaldehyde diethyl acetal is deprotected to generate dimethyl amino acetaldehyde.
Weighing 4.5g of the intermediate III, placing the intermediate III in a 250ml three-necked bottle, adding 50ml of ethanol and 40ml of ethanol solution of dimethylaminoacetaldehyde, stirring and dissolving, cooling to 0 ℃ in an ice bath, beginning to dropwise add 25g of 35% LiOH aqueous solution, controlling the temperature to be 10-15 ℃, after finishing dripping, naturally heating to room temperature, after the reaction is finished, pouring the reaction liquid into 300ml of water, stirring and crystallizing for 2 hours, performing suction filtration, and drying to obtain an intermediate II, wherein the yield is 72.1%, and the purity is 95.1%.
The fourth step
Weighing 4.0g of the intermediate II, placing the intermediate II in a 250ml three-necked bottle, adding 50ml of n-hexane, adding 1.0g of (S) -3-hydroxytetrahydrofuran, slowly adding sodium hydroxide, controlling the temperature to be not more than 50 ℃, stirring for reacting for 1h, pouring the reaction liquid into 100ml of drinking water after the reaction is finished, adjusting the pH value to be 6.5 by using 10% acetic acid aqueous solution, performing suction filtration, and drying to obtain afatinib I, wherein the yield is 74% and the purity is 94.0%.

Claims (8)

1. An afatinib intermediate II has a structural formula as follows:
Figure 25006DEST_PATH_IMAGE001
。
2. a preparation method of an afatinib intermediate II is characterized by comprising the following steps: reducing N- (3-chloro-4-fluorophenyl) -7-fluoro-6-nitro-4-quinazolinamine V as an initial raw material to obtain N- (3-chloro-4-fluorophenyl) -7-fluoro-6-amino-4-quinazolinamine IV, carrying out condensation reaction with diethylphosphonoacetic acid to obtain III, carrying out Wittig-Horner-Emmons reaction with dimethylaminoacetal diethyl acetal to obtain a key intermediate II,
the method specifically comprises the following steps:
1) Reduction reaction: adding the starting material V, a reducing agent, a catalyst and an organic solvent A into a reaction bottle for reduction reaction to obtain a compound IV;
2) Condensation reaction: adding the compound IV, diethylphosphonoacetic acid, a condensing agent and an organic solvent B into a reaction bottle for condensation reaction to obtain a compound III;
3) Wittig-Horner-Emmons reaction: adding a compound III, dimethylamino acetaldehyde diethyl acetal, concentrated hydrochloric acid, an organic solvent C and alkali A into a reaction bottle for reaction to obtain a compound II,
Figure 104957DEST_PATH_IMAGE002
，
the catalyst in the reduction reaction is selected from 10% Pd/C, Zn, Fe (OH)3、FeO(OH)、FeCl3Or Fe (OAc)2The adding amount of the catalyst is 0.03-0.05 time of the intermediate V; the alkali A in the wittig-Horner-Emmons reaction is selected from one of potassium hydroxide, sodium hydroxide, lithium hydroxide and cesium hydroxide.
3. The method for preparing afatinib intermediate ii according to claim 2, wherein organic solvent a, organic solvent B, and organic solvent C are each independently selected from aromatic hydrocarbons, aliphatic hydrocarbons, alicyclic hydrocarbons, halogenated hydrocarbons, alcohols, ethers, amides, glycol derivatives, ester solvents, or phenols.
4. The method for preparing afatinib intermediate ii according to claim 3, wherein organic solvent a, organic solvent B and organic solvent C are each independently selected from one or more of benzene, toluene, cyclohexane, methanol, ethanol, tert-butanol, diethyl ether, acetone, trichloroethylene, tetrahydrofuran, methyl tert-butyl ether, ethyl acetate or DMF.
5. The method for preparing afatinib intermediate II according to claim 4, wherein the organic solvent a is selected from one or more of tert-butanol, diethyl ether, acetone, trichloroethylene, tetrahydrofuran, methyl tert-butyl ether, ethyl acetate and DMF.
6. The preparation method of afatinib intermediate II according to claim 5, wherein the organic solvent a is tert-butanol or acetone or a mixed solution of the two.
7. The method for preparing afatinib intermediate ii according to claim 2, wherein the catalyst in the reduction reaction is FeCl3Or 10% Pd/C.
8. The method for preparing afatinib intermediate ii according to claim 2, wherein the reducing agent in the reduction reaction is selected from hydrogen, ammonium formate, hydrazine hydrate or ammonium chloride.
CN201610411343.6A 2016-06-10 2016-06-10 Afatinib intermediate compound Active CN107488153B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610411343.6A CN107488153B (en) 2016-06-10 2016-06-10 Afatinib intermediate compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610411343.6A CN107488153B (en) 2016-06-10 2016-06-10 Afatinib intermediate compound

Publications (2)

Publication Number Publication Date
CN107488153A CN107488153A (en) 2017-12-19
CN107488153B true CN107488153B (en) 2020-06-23

Family

ID=60643286

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610411343.6A Active CN107488153B (en) 2016-06-10 2016-06-10 Afatinib intermediate compound

Country Status (1)

Country Link
CN (1) CN107488153B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1867564A (en) * 2003-10-17 2006-11-22 贝林格尔·英格海姆国际有限公司 Process for preparing amino crotonyl compounds
CN104151359A (en) * 2014-07-15 2014-11-19 杭州华东医药集团新药研究院有限公司 Quinazoline compound as well as preparation method and application thereof in preparing tyrosine kinase inhibitor
CN104926798A (en) * 2014-03-21 2015-09-23 江苏豪森药业股份有限公司 High purity preparation method of Afatinib intermediate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1867564A (en) * 2003-10-17 2006-11-22 贝林格尔·英格海姆国际有限公司 Process for preparing amino crotonyl compounds
CN104926798A (en) * 2014-03-21 2015-09-23 江苏豪森药业股份有限公司 High purity preparation method of Afatinib intermediate
CN104151359A (en) * 2014-07-15 2014-11-19 杭州华东医药集团新药研究院有限公司 Quinazoline compound as well as preparation method and application thereof in preparing tyrosine kinase inhibitor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Disclosed Anonymously.Process for the preparation of afatinib.《IP.COM Journal》.2015,第15卷(第10A期), *
Process for the preparation of afatinib;Disclosed Anonymously;《IP.COM Journal》;20150930;第15卷(第10A期);第1-3页 *

Also Published As

Publication number Publication date
CN107488153A (en) 2017-12-19

Similar Documents

Publication Publication Date Title
CN103012124B (en) Preparation method of 3,6-dichloro-2-hydroxybenzoic acid
CN103012123A (en) Synthetic method for 3,6-dichloro-2-hydroxybenzoic acid
CN107488153B (en) Afatinib intermediate compound
CN111807973B (en) Preparation method of vilanterol and salt thereof
CN107488152B (en) Afatinib intermediate and synthetic method thereof
CN107488194B (en) Afatinib intermediate and preparation method thereof
CN107488171B (en) Preparation method of afatinib
CN107056681B (en) A kind of support method replaces the preparation method of cloth intermediate
CN104710413B (en) The preparation method of two maleic acid Afatinibs
CN105884644B (en) Neutral endopeptidase inhibitor salt dominant form and preparation method thereof
CN113087622A (en) Preparation method of eptazocine intermediate
CN112028896A (en) Novel crystal form of acatinib and preparation method thereof
CN116693437A (en) A kind of synthetic method of N-Boc-3-azetidine acetic acid
CN114957134B (en) Method for preparing azoxystrobin and intermediate thereof
CN107488172B (en) Preparation method of afatinib
CN110759848A (en) Ethanesulfonic acid nintedanib impurity as well as preparation method and application thereof
CN111100042B (en) Preparation method of 2-methoxy-5-sulfonamide benzoic acid
CN113956239A (en) Azelastine hydrochloride, and preparation method and application thereof
CN112920233A (en) Synthetic method of emamectin benzoate with improved processability
IL290215B1 (en) Process for preparing the crystalline form ii of sotagliflozin
CN118812418B (en) A kind of preparation method of high-purity arecoline hydrobromide
CN118271291B (en) A preparation method and application of high-purity azelastine hydrochloride
US10611721B2 (en) Method for preparing levobunolol hydrochloride
CN116947691B (en) Preparation method of fluvoxamine maleate
CN113372314B (en) High-purity furandiene crystal and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: An intermediate compound of afatinib

Effective date of registration: 20211224

Granted publication date: 20200623

Pledgee: Industrial and Commercial Bank of China Limited Feixian sub branch

Pledgor: SHANDONG NEW TIME PHARMACEUTICAL Co.,Ltd.

Registration number: Y2021980016193

PE01 Entry into force of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Date of cancellation: 20221028

Granted publication date: 20200623

Pledgee: Industrial and Commercial Bank of China Limited Feixian sub branch

Pledgor: SHANDONG NEW TIME PHARMACEUTICAL Co.,Ltd.

Registration number: Y2021980016193

PC01 Cancellation of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: An intermediate compound of alfatinib

Effective date of registration: 20221103

Granted publication date: 20200623

Pledgee: Industrial and Commercial Bank of China Limited Feixian sub branch

Pledgor: SHANDONG NEW TIME PHARMACEUTICAL Co.,Ltd.

Registration number: Y2022980020531

PE01 Entry into force of the registration of the contract for pledge of patent right